AXDX
Accelerate Diagnostics, Inc.
Set alert
52-week range unavailable
- Open
- 0.08
- Prev close
- 0.034
- Mkt cap
- 26.80M
- Vol
- 13.82M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.034
- High
- 0.08
- Forward P/E
- -0.63
- Beta
- 0.60
- Short ratio
- 7.77
- Inst. own
- 17.45%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.68
- 200-d avg
- 1.38
- 1y target
- 0.00
Key statistics
- Market cap
- 26.80M
- Enterprise value
- 79.31M
- Trailing P/E
- 0.00
- Forward P/E
- -0.63
- PEG ratio
- 0.00
- Price / sales
- 2.19
- Price / book
- 0.00
- EPS (TTM)
- -2.59
- Beta
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 12.23M
- Revenue growth
- 2.20%
- Free cash flow
- -54.67M
- Total cash
- 9.75M
- Total debt
- 42.41M
- Return on equity
- 0.00%
- Shares outstanding
- 25.04M
- Short % of float
- 3.05%
- 50-day average
- 1.68
- 200-day average
- 1.38
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.47 | -0.59 | -0.12 | -25.53% |
| Aug 8, 2024 | Jun 1, 2024 | -0.55 | -0.50 | +0.05 | +9.09% |
| May 8, 2024 | Mar 1, 2024 | -0.72 | -0.88 | -0.16 | -22.22% |
| Mar 28, 2024 | Dec 1, 2023 | -0.62 | -0.89 | -0.27 | -43.55% |
| Nov 9, 2023 | Sep 1, 2023 | -0.94 | -0.92 | +0.02 | +2.13% |
| Aug 10, 2023 | Jun 1, 2023 | -1.50 | -2.36 | -0.86 | -57.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 1, 2024 | Craig-Hallum | main | Hold | Hold |
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- acceleratediagnostics.com
News
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Your note
Sign in to keep a note on AXDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURRIS WAYNE C. | Director | Conversion of Exercise of derivative security | May 30, 2024 | 1,678 |
| FRANCESCONI LOUISE L | Director | Conversion of Exercise of derivative security | Jun 27, 2024 | 33,558 |
| MASSARANY HANY | Director | Conversion of Exercise of derivative security | Jun 27, 2024 | 39,891 |
| MERTZ LARRY MICHAEL | Chief Technology Officer | Sale | May 19, 2024 | 82,028 |
| PATIENCE DAVID | Chief Financial Officer | Sale | Apr 8, 2024 | 51,179 |
| PATIENCE JOHN | Director | Purchase | Dec 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.39% | 2,101,000 | 2.25M | Sep 29, 2024 |
| Griffin Asset Management, Inc. | 4.97% | 1,245,355 | 1.33M | Sep 29, 2024 |
| Vanguard Group Inc | 1.89% | 473,034 | 506.15K | Sep 29, 2024 |
| Birchview Capital, LP | 1.30% | 325,239 | 348.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.51% | 126,955 | 135.84K | Sep 29, 2024 |
| Cannell & Spears LLC | 0.46% | 114,523 | 122.54K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.52% | 381,456 | 408.16K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 90,274 | 96.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 74,964 | 80.21K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 17,826 | 19.07K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 15,064 | 16.12K | Oct 30, 2024 |
| Thompson Mid Cap Fund | 0.04% | 10,390 | 11.12K | Sep 29, 2024 |